Company: BIVIW
Filing Date: 2025-08-08
Form Type: 424B5
Source: 0001520138-25-000247
Chunk: 54

Company: BIOVIE INC.
Filing Date: 2025-08-08
Form: 424B5
Chunk 54
---
 addition, the uncertainties
associated with litigation could compromise our ability to raise the funds necessary to continue our clinical trials, continue our internal
research programs, or in-license needed technology or other drug candidates. There could also be public announcements of the results of
the hearing, motions, or other interim proceedings or developments. If securities analysts or investors perceive those results to be negative,
it could cause the price of shares of our Common Stock to decline. Any of the foregoing events could harm our business, financial condition,
results of operation and prospects.

<div align='center'>25</div>

We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might subject us to infringement claims or adversely affect our ability to develop and market our drug candidates.

We cannot guarantee that any of our or our licensors’
patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant
patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending patent
application in the United States and abroad that is relevant to or necessary for the commercialization of our drug candidates in any jurisdiction.
For example, U.S. patent applications filed before November 29, 2000 and certain U.S. patent applications filed after that date that will
not be filed outside the United States remain confidential until patents issue. As mentioned above, patent applications in the United
States and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest
filing date being commonly referred to as the priority date. Therefore, patent applications covering our drug candidates could have been
filed by third parties without our knowledge. Additionally, pending patent applications that have been published can, subject to certain
limitations, be later amended in a manner that could cover our drug candidates or the use of our drug candidates. The scope of a patent
claim is determined by an interpretation of the law, the written disclosure in a patent and the patent’s prosecution history. Our
interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability
to market our drug candidates. We may incorrectly determine that our drug candidates are not covered by a third-party patent or may incorrectly
predict whether a third party’s pending application will issue with claims of relevant scope. Our determination of the expiration
date of any patent in the United States or abroad that